Published in Health and Medicine .
2013 MAR 1 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Neurodegenerative Diseases have been published. According to news reporting originating from Logrono, Spain, by NewsRx correspondents, research stated, "Alzheimer's disease is characterized by the abnormal aggregation of amyloid-ß (Aß)1-40 and Aß1-42 peptides into fibrils. In this work, we analyzed the kinetics of Aß1-40 and Aß1-42 fibril formation in vitro using Thioflavin T fluorescence."
Our news editors obtained a quote from the research from Araclon Biotech Ltd., "We synthesized high-purity peptides and performed a...
...
■Purchase this article for only $3.00
PharmaMar Recibe el Ok de la FDA Para Iniciar Fase I con PM54 en Combi con Inmuno Para Posible Tratamiento . PARA EI RELEVO DE LURBINECTEDIN ESTABAN PM184 Y PM14 AMBOS RETIRADOS POR LA CIA. AHORA HAY OTROS DOS FÁRMACOS EN FASE I EN EL INTENTO DE RELEVAR A LURBINECTEDIN : PM54 Y PM534 ... EL PROBLEMA ES QUE AMBOS AÚN ESTAN EN FASE I CON TODO LO QUE ESTO IMPLICA EN CUESTIÓN DE PLAZOS ... YA QUE PARA REALUZAR 3 FASES CLÍNICAS HACEN FALTA DE 12 A 15 AÑOS ... NOS IRÍAMOS AL 2040.